During the severe stage of COVID-19, the inhibition of the IL-6 receptor (IL-6R) is being tested in clinical trials, and it has shown promising results in decreasing the cytokine release syndrome in COVID-19 patients (148). The gene discussed is IL6R; the disease is COVID-19.